First Ever Dry Nasal Inhaler (QNASL™) Approved by FDA to Give Allergy Sufferers Relief
Groundbreaking Dry Nasal Spray Released in U.S. Market as of April 2012
San Antonio, TX [April 24, 2012] — Teva Pharmaceutical Industries Ltd., announced as of April 2012, that QNASL™ (beclomethasone dipropionate), a new, nonaqueous "dry" nasal inhaler, has been approved by the U.S. Food and Drug Administration (FDA) as a prescribed medication. Allergies are most effectively treated by intranasal inhalers, which up until the release of QNASL™ remedied symptoms by spraying a liquid solution in the nasal cavity that resulted in the sensation of the medication dripping down the throat. A study published by the National Allergy Survey Assessing Limitations revealed that 81% percent of patients were less satisfied with their nasal inhaler when they felt it trickling in their throat than other patients who did not experience the dripping of the medication.
“The QNSAL™ dry nasal inhaler is a great medicinal breakthrough because it is exceptionally designed with the patient in mind,” said Dr. Mirie Hosler of Allergy, Asthma & Immunology Associates of South Texas, a group of allergy clinics serving the South Texas region since 1988. Allergy, Asthma & Immunology Associates of South Texas also participated in the phase 2 studies of clinical research trials for QNSAL™ that eventually led to its FDA approval. The first of its kind dry nasal inhaler will be available by prescription only for the treatment of nasal symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) and offers a new innovative treatment that is both safe and effective for adults and adolescents 12 years of age and older.
The procurement of an alternative medication to treat allergies is a welcome relief when taking into consideration that the National Allergy Survey Assessing Limitations found that nasal allergy patients ranked their productivity 20% less than normal when their nasal allergies were at their worst.Nationwide, the American Academy of Allergy Asthma Immunology calculates that allergic rhinitis affects between 10% and 30% of all adults and as many as 40% of children in the U.S. An estimated 4 million work days and 2 million school days are lost each year because of nasal allergies as stated by the Allergy and Asthma Foundation of America. Moreover, the National Allergy Survey Assessing Limitations also concluded that nasal allergy patients were three times as likely to be troubled by difficulty in falling asleep.
“When you take into consideration the millions of work and school days missed due to allergies, inability to sleep, and the overall reduction in quality of life,” said Dr. Hosler,” it is crucial to note that in many cases allergies can be controlled through medication. A dry nasal inhaler, such as QNSAL™, presents another therapy option for a patient that is just as effective as a liquid nasal spray and is more likely to be tolerated.”
About Allergy, Asthma and Immunology Associates of South Texas
Since 1988, Allergy, Asthma and Immunology Associates of South Texas have treated pediatric and adult patients with state of the art medical care in a friendly and efficient atmosphere. Our board certified physicians and health care providers search for triggers that cause diseases and symptoms in various parts of the body and employ treatments that control or halt the disease process. Our mission is to enhance the quality of life for our patients and their families by providing them with comprehensive medical service in a timely and caring manner. For more information, please visit www.allergysa.com.
About Dr. Mirie Hosler
After a distinguished career with University Hospitals-Allergy & Asthma Center in Westlake, OH, Dr. Mirie Hosler joined Allergy, Asthma & Immunology Associates of South Texas. She attended medical school at Northwestern University, and graduated magna cum laude from the university’s distinguished Medical Education Honors Program. In 1997, Dr. Hosler fulfilled her residency in Internal Medicine at Evanston Northwestern Hospital and completed her fellowship in Allergy/Immunology at Rush-Presbyterian-St. Luke’s Medical Center in Chicago.